In this study, we showed that the frequency of FLT3 mutation in AML patients was higher than in the control group and functions as an essential marker in the diagnosis and prognosis of AML disease; these results are consistent with the previous studies32–35. This evidence concerns the gene FLT3 and acute myeloid leukemia.